What is the Ayala Pharmaceuticals Inc. stock price forecast?

Ayala Pharmaceuticals Inc. is currently trading at $0.60. View real-time AI analysis on Alpha Lenz.

What is Ayala Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Ayala Pharmaceuticals Inc. on Alpha Lenz.

What is Ayala Pharmaceuticals Inc.'s P/E ratio?

Ayala Pharmaceuticals Inc.'s P/E ratio is -0.1.

Ayala Pharmaceuticals Inc.

NASDAQ · ADXS

$0.60+0.00(+0.00%)Pre-market

Ask about Ayala Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Ayala Pharmaceuticals Inc. trades at a P/E of -0.1 (undervalued) with strong ROE of 376.8%.”

Ask for details →

Company Overview

Ayala Pharmaceuticals Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of innovative oncology therapies. The company’s core focus is on creating small molecule therapeutics and immunotherapies for patients with rare tumors and aggressive cancers. Ayala’s portfolio includes lead candidates such as AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), a novel anti-metabolite designed for first-line treatment in unfit acute myeloid leukemia patients. Utilizing proprietary technology platforms like its engineered Listeria monocytogenes (Lm) antigen delivery system, the company aims to activate and direct cancer-fighting T cells, supporting the next generation of targeted cancer treatments. Through strategic partnerships with other biopharmaceutical firms and a commitment to expanding its research pipeline, Ayala Pharmaceuticals plays a significant role in the evolving landscape of oncology drug development, advancing options for conditions with high unmet medical need.

CEOMr. Kenneth A. Berlin J.D.

Websitehttps://www.ayalapharma.com

SectorHealthcare

IndustryBiotechnology

Employees20

Company Statistics

FY 2023

Profile

$3.63MMarket Cap

$13.00KRevenue

0.00Shares Out

20Employees

Margins

0.00%Gross

-275915.38%EBITDA

-278969.23%Operating

-399876.92%Pre-Tax

-369784.62%Net

Valuation

-0.08P/E

-0.15P/B

279.47EV/Sales

-0.20EV/EBITDA

-0.12P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-394.87%ROA

376.80%ROE

-297.67%ROIC

Financial Health

$4.88MCash & Cash Equivalents

$36.11MNet Debt

-167.90%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Ayala Pharmaceuticals Inc. trades at a P/E of -0.1 (undervalued) with strong ROE of 376.8%.”

Ask for details →

Frequently Asked Questions

Ayala Pharmaceuticals Inc. (ticker: ADXS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $4M.

The current price is $0.604 with a P/E ratio of -0.08x and P/B of -0.15x.

ROE is 376.80% and operating margin is -278969.23%. Annual revenue is $13,000.